Document Detail

Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality.
MedLine Citation:
PMID:  16043795     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), the most frequently used lipid-lowering agents (LLAs) have neuroprotective effects in rodent models of ischemic stroke. The authors hypothesized that patients with ischemic stroke taking LLAs would have better outcomes than patients not taking LLAs. METHODS: The Northern Manhattan Study is a population-based study designed to determine stroke incidence and prognosis in a multiethnic, urban population. Northern Manhattan residents age 40 years or older diagnosed with their first ischemic stroke were eligible. Patients or their proxies were interviewed regarding medications being taken at home before stroke onset. The NIH Stroke Scale was used to assess stroke severity, categorized as mild (< or =5), moderate (6 to 13), or severe (> or =14), and the Barthel Index at 6 months to assess functional outcome. Clinical worsening in hospital was recorded by trial neurologists. Odds ratios and 95% CIs for association of LLA use and stroke severity, mortality, and functional outcome were calculated using logistic regression. RESULTS: Of 650 patients, 57 (8.8%) were taking LLAs. The majority (90.9%) of LLA users were taking a statin. Clinical worsening in hospital occurred less frequently among patients taking LLAs at stroke onset (6.3% vs 18.2%; p = 0.04). Ninety-day mortality was lower in those taking LLAs (1.8% vs 10.6%, p = 0.03). The proportion of patients with severe stroke among those taking LLAs was not lower (10.7% vs 16.8%, p = 0.39). CONCLUSION: Patients taking lipid-lowering agents (LLAs) at the time of an ischemic stroke may have lower poststroke mortality and a lower risk of worsening during hospitalization. Prospective studies are warranted to determine whether LLAs, and statins in particular, have neuroprotective properties or other beneficial effects in acute ischemic stroke.
Mitchell S V Elkind; Alexander C Flint; Robert R Sciacca; Ralph L Sacco
Related Documents :
10393405 - Mapping the ischaemic penumbra with pet: implications for acute stroke treatment.
14742615 - Isolated pulmonary arteriovenous fistula without rendu-osler-weber disease as a cause o...
17159455 - Increased risk of treatment with antidepressants in stroke compared with other chronic ...
15781825 - Sonothrombolysis in acute ischemic stroke for patients ineligible for rt-pa.
3292245 - Antibacterial capacity of buccal epithelial cells from healthy donors and children with...
22572525 - The relationship between copper and steatosis in wilson's disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurology     Volume:  65     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-26     Completed Date:  2006-01-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  253-8     Citation Subset:  AIM; IM    
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Brain Ischemia / drug therapy*,  mortality*,  prevention & control
Cohort Studies
Disease Progression
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Neuroprotective Agents / therapeutic use
Stroke / drug therapy*,  mortality*,  prevention & control
Treatment Outcome
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Neuroprotective Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.
Next Document:  APOE, vascular pathology, and the AD brain.